| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
OAC-1 (also known as BAS 00287861) is an Oct-4 (Octamer-binding transcription factor-4) activator which enhances and accelerates iPSC reprogramming in the presence of 4F (Oct-4, Sox-2, c-Myc and GKLF) by ~20-fold (relative to 4F by itself). OAC-1 upregulates mRNA expression of Oct-4, Sox-2 and Nanog, as well as Tet1. It has shown no effects, however, on the p53-p21 pathway or Wnt-β-catenin signaling. In luciferase reporter assays, OAC1 activated both human Oct4 and Nanog promoter-driven luciferase reporter genes.
| ln Vitro |
OAC1 (10 μM; 7 d) improves the effectiveness of reprogramming. OAC1 promotes the production of induced pluripotent stem cells (iPSCs) from mouse embryonic fibroblasts (MEFs) and speeds up the development of colonies that resemble iPSCs[1]. Human IMR90 fibroblast cells) stimulate the production of Tet1, Oct4, Nanog, and Sox2 endogenously[1]. The number of functional hematopoietic progenitor cells (HPC) and phenotypic hematopoietic stem cells (HSC) is increased by OAC1 (500 nM; 4 d; CD34+ cells)[2]. Hematopoietic stem cells (HSC) can be expanded by OAC1 (500 nM; 4 d; CD34+ cells) activating OCT4 through elevation of HOXB4 expression[2].
|
|---|---|
| ln Vivo |
In irradiated NSG mice, OAC1 (50000 CB CD34+ cells with OAC1(500 nM); i.e., 16 weeks) improves both the short- and long-term engrafting of hematopoietic stem cells (HSC)[2].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: CD34+ cells from human cord blood Tested Concentrations: 500 nM Incubation Duration: 4 days Experimental Results: Increased the numbers of CD34+CD38- cells. Increased the number of Lin-CD34+CD38-CD45RA-CD90+CD49f+ cells. Increased in the number of phenotypic hematopoietic stem cells (HSC) compared to control vectors. Enhanced expansion of HPC with both full and suboptimal cytokine doses in the expansion and colony forming phases. |
| Animal Protocol |
Animal/Disease Models: Irradiated NSG mice with OAC1 or vehicle control treated CB CD34+ cells within 24h after irradiation[2]
Doses: 16 weeks Route of Administration: subcutaneous (sc) injection OAC1(500 nM) treated CB CD34+ cells Experimental Results: Increased cord blood (CB) cells in primary recipients, compared to the vehicle control group, with the board increase for human B cells, T cells, and myeloid cells in the bone marrow (BM) of primary recipients, resulting in a significant expansion of SRC numbers. |
| References |
|
| Molecular Formula |
C14H11N3O
|
|
|---|---|---|
| Molecular Weight |
237.26
|
|
| Exact Mass |
237.09
|
|
| CAS # |
300586-90-7
|
|
| Related CAS # |
|
|
| PubChem CID |
789882
|
|
| Appearance |
Off-white to gray solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
386.6±22.0 °C at 760 mmHg
|
|
| Flash Point |
187.6±22.3 °C
|
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
|
| Index of Refraction |
1.755
|
|
| LogP |
1.19
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
2
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
18
|
|
| Complexity |
301
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
HWJRIFZDXJKJJN-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C14H11N3O/c18-14(10-4-2-1-3-5-10)17-13-8-11-6-7-15-12(11)9-16-13/h1-9,15H,(H,16,17,18)
|
|
| Chemical Name |
N-(1H-pyrrolo[2,3-c]pyridin-5-yl)benzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2148 mL | 21.0739 mL | 42.1479 mL | |
| 5 mM | 0.8430 mL | 4.2148 mL | 8.4296 mL | |
| 10 mM | 0.4215 mL | 2.1074 mL | 4.2148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
